ADC Therapeutics SA (ADCT)

Market Cap	89.51M
Revenue (ttm)	122.57M
Net Income (ttm)	-178.51M
Shares Out	80.64M
EPS (ttm)	-2.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	411,587
Open	1.09
Previous Close	1.11
Day's Range	0.97 - 1.09
52-Week Range	0.36 - 5.75
Beta	1.24
Analysts	Hold
Price Target	4.20 (+307.77%)
Earnings Date	Nov 7, 2023

About ADCT

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a mon...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 15, 2020
• Employees: 317
• Stock Exchange: NYSE
• Ticker Symbol: ADCT

Financial Performance

In 2022, ADCT's revenue was $209.91 million, an increase of 518.89% compared to the previous year's $33.92 million. Losses were -$155.80 million, -32.27% less than in 2021.

Analyst Forecast

According to 7 analysts, the average rating for ADCT stock is "Hold." The 12-month stock price forecast is $4.2, which is an increase of 307.77% from the latest price.

Price Target

$4.2

(307.77% upside)

Analyst Consensus: Hold